This course is designed for medical practitioners, nurses, addiction medicine specialists and other clinical staff working with people who inject drugs. Through online learning and a face-face workshop, delivered by local experts, participants will gain the skills to confidently manage hepatitis C in their setting.

People who inject drugs (PWID) represent approximately 90% of newly acquired hepatitis C (HCV) infections. Clinicians working with PWID play an important role in reducing HCV-related morbidity and mortality through early diagnosis and treatment.

With the advent of new, well-tolerated, short-course direct acting antiviral (DAA) HCV regimens with cure rates >95%, there is an opportunity to vastly improve the health outcomes of people living with HCV.

At the conclusion of this program, participants will be able to:

- Describe the risk factors for HCV infection, enabling effective practice screening processes and prevention education
- Demonstrate competence interpreting clinical information to effectively diagnose HCV
- Demonstrate competence in liver disease assessment
- Demonstrate understanding of DAA therapy for the treatment of HCV and competence in selecting and prescribing appropriate therapy
- Monitor patients on treatment and post-treatment appropriately

Date: Monday, 04 November 2019

Time: 8:30am - 4:00pm

Venue: Calgary Marriott Downtown Hotel
110 9th Ave SE
Calgary, AB T2G 5A6, Canada

Cost: The course is free of charge and fully catered. Places are limited - registration is essential.

Registration link: https://ashm.eventsair.com/calgary-4-november-2019-hep-c/registration/Site/Register

Register before: Friday, 1st November 2019

More information: For further details contact education@ashm.org.au

Certification
This Group Learning program has been reviewed by the College of Family Physicians of Canada and is awaiting provincial certification by the College’s AB Chapter.

About INHSU
This Symposium is convened by the International Network on Hepatitis in Substance Users (INHSU), an international organization dedicated to scientific knowledge exchange, knowledge translation, and advocacy focused on hepatitis C prevention and care among people who use drugs.

This workshop has been funded through an unrestricted grant from AbbVie Canada and Gilead Sciences Canada. AbbVie and Gilead have had no input into the tone, content or emphasis of the material used at this course.